Skip to main content

Table 2 Health care quality indicators according to cardiovascular risk

From: Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

 

Moderate risk

High risk

Very high risk

p

HbA1c ≤ 7.0% (%)

57.4

58.0

51.6

 < 0.0001

HbA1c > 8.0% (%)

22.3

16.1

18.4

 < 0.0001

Blood pressure ≥ 140/90 mmHg (%)

0.0

31.0

50.8

 < 0.0001

LDL Cholesterol < 100 mg/dl (%)

49.8

54.7

65.6

 < 0.0001

LDL Cholesterol ≥ 130 mg/dl (%)

0.0

9.1

13.1

 < 0.0001

Subjects with HbA1c ≤ 7.0%, with C-LDL < 100 mg/dl and with BP < 140/90 mmHg (%)

31.0

24.3

18.6

 < 0.0001

BMI ≥ 30 kg/m2(%)

0.0

14.7

46.6

 < 0.0001

Subjects not treated with insulin despite HbA1c ≥ 9.0% (%)a

39.2

38.4

25.5

 < 0.0001

Subjects with HbA1c ≥ 9.0% despite insulin therapy (%)b

31.6

18.2

15.7

 < 0.0001

Subjects not treated with anti-hypertensive despite BP ≥ 140/90 mmHg (%)c

n.a

48.2

22.5

 < 0.0001

Subjects with BP ≥ 140/90 mmHg despite anti-hypertensive therapy (%)d

n.a

46.8

48.8

 < 0.0001

Subjects not treated with lipid-lowering drugs despite C-LDL ≥ 130 mg/dl (%)e

n.a

60.1

45.5

 < 0.0001

Subjects with C-LDL ≥ 130 mg/dl despite lipid-lowering therapy (%)f

n.a

16.9

9.7

 < 0.0001

Subjects with a previous CV event (heart attack and/or stroke) treated with antiplatelet therapy (%)

n.a

n.a

76.1

-

Mean Q Score

32.2 ± 6.8

30.1 ± 7.6

28.2 ± 8.3

 < 0.0001

Subjects with Q Score < 15 (%)

0.0

1.6

4.1

 < 0.0001

Subjects with Q Score > 25 (%)

74.0

66.1

59.4

 < 0.0001

  1. aDenominator: all the subjects with HbA1c ≥ 9.0%
  2. bDenominator: all the subjects treated with insulin
  3. cDenominator: all the subjects with BP ≥ 140/90 mmHg
  4. dDenominator: all the patients treated with anti-hypertensive drugs
  5. eDenominator: all the subjects with C-LDL ≥ 130 mg/dl
  6. fDenominator: all the subjects treated with lipid-lowering drugs
  7. n.a. notapplicable